LAS VEGAS, Feb. 15 /Xinhua-PRNewswire-FirstCall/ -- China Health Holding, Inc. , a development stage company with the goal of becoming a leading developer, manufacturer, marketer and distributor of pharmaceutical drugs and dietary supplements in China and worldwide, today announced that it has appointed Dr. Zhenglun Fan to the Company’s board of directors and has appointed him to serve on the Nominating Committee and the Corporate Governance Committee.
Julianna Lu, Founder and CEO of China Health Holding commented, “We are honored and pleased Dr. Fan has accepted this new position. In this role, he will continue to help advance China Health’s mission to commercialize Traditional Chinese Medicine and to build a leading pharmaceutical company in China and worldwide. We are confident that his experience and expertise in the Chinese economy, cross-cultural business practices, acquisition, management and business development, as well as his commitment to the company and its shareholders, will add significantly to the company’s strength and growth potential. We are confident that his expertise working with Traditional Chinese Medicine will help China Health continue to develop a comprehensive pipeline of SFDA accredited drugs and further accomplishment of acquisitions with major pharmaceutical companies in China and worldwide.”
Since 2005, Dr. Fan has served China Health as Vice President of Research & Development. Additionally, for the past years, he has been a professor of research at the Cui Yue-li Research Center of Traditional Chinese Medicine in Beijing. Recognized nationally in China for his work, Dr. Fan has studied and practiced Traditional Chinese Medicine for more than 40 years.
Ms. Lu continued, “Mr. Fan’s addition not only brings many years of TCM experience to the team, but brings us one step closer to building a world- class pharmaceutical company committed to providing the highest standards of corporate governance. We are honored to have his guidance and knowledge as we implement our ambitious acquisition growth strategy and help us better prepare for a listing on a larger exchange such as NASDAQ or American Stock Exchange in the next 12 to 18 months.”
In the next 12 to 24 months, the Company intends to continue partnering with China SFDA certified drugs producers; China GMP accredited manufacturing facilities, research and development centers and Universities. Further pending acquisitions are expected to bring total assets to US$100 million, gross revenue of approximately US$100 million and an annual net income of US$10-15 million.
About China Health Holding
China Health Holding, Inc. is a development stage company with the goal of becoming a leading developer, manufacturer, marketer and distributor of pharmaceutical products and dietary supplements in China and worldwide. It has extensive expertise in the field of traditional Chinese medicine and the Chinese pharmaceutical industry. Its immediate goal is the profitable penetration of the growing global and China pharmaceutical industry and market through acquisitions of major pharmaceutical companies in the People’s Republic of China and worldwide. Its long-term plans include the development of a pharmaceutical drug pipeline and technology based on its knowledge of traditional Chinese medicine and the pharmaceutical industry in the People’s Republic of China.
The company has two wholly-owned subsidiaries: (i) China Health World Pharmaceutical Corporation, which will develop, manufacture and commercialize natural medications for diseases and conditions related to diabetes, cardiovascular disease and neurological disorders; and (ii) China Health World Trade Corporation, which will develop China Health’s retail/franchise infrastructure along with worldwide branding, multimedia marketing and multi- channel distribution to global customers and markets.
China Health owns the exclusive worldwide rights to a total of 134 proprietary natural herbal medicinal products/formulas in two natural herbal medicinal product lines: King of Herbs and Taoist Medicinal. Please visit http://www.chinahealthholding.com for the Company’s profile.
For investor and media inquiries, please contact: China Health Holding, Inc. (Las Vegas) Xiaofei Yu, President Tel: +1-604-608-6788, or +1-877-883-0979 Tel: 86-10-1370-133-1287 (Beijing China)(Text Message) Email: info@chinahealthholding.comhttp://www.chinahealthholding.com Or, in North America: Haris Tajyar, Managing Partner Investor Relations International +1-818-382-9702 Email: htajyar@irintl.com Or, in China, HongKong, Asia and Rest of World: Rory Macpherson Senior Associate Ogilvy Public Relations Worldwide +86-10-8520-6553 Email: rory.macpherson@ogilvy.com
Safe Harbor Statement: To the extent that statements in the press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward looking, all forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements, which may accompany the forward-looking statements, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Other important factors that could cause actual results to differ materially include the following: business conditions and the amount of growth in the Company’s industry and general economy; competitive factors; ability to attract and retain personnel; the price of the Company’s stock; and the risk factors set forth from time to time in the Company’s SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. In addition, the company disclaims any obligation to update or correct any forward-looking statements in all of the Company’s press releases to reflect events or circumstances after the date hereof.
China Health Holding, Inc.
CONTACT: Xiaofei Yu, President of China Health Holding, Inc.,+1-604-608-6788, or +1-877-883-0979, or Text Message (China),+86-10-1370-133-1287, or info@chinahealthholding.com; or Haris Tajyar,Managing Partner of Investor Relations International, +1-818-382-9702, orhtajyar@irintl.com; or Rory Macpherson, Senior Associate of Ogilvy PublicRelations Worldwide, +86-10-8520-6553, or rory.macpherson@ogilvy.com
Web site: http://www.chinahealthholding.com/
